Newer prostate Ca agent shows positive pain outcomes

Recent studies of the oral androgen receptor inhibitor enzalutamide (Xtandi) evaluated the effect of costicosteroid use with the agent as well as its pain-related outcomes in patients with advanced prostate cancer.

Related Videos
Rachel Pope, MD, MPH, answers a question during a Zoom interview
blur image background of corridor in hospital or clinic image | Image credit: © whyframeshot - stock.adobe.com
Dr. David Canes in an interview with Urology Times
Urinary bladder | Image credit: © magicmine - stock.adobe.com
Blurred interior of hospital | Image credit: © jakkapan - stock.adobe.com
Blurry hospital corridor | Image credit: © zephyr_p - stock.adobe.com
Ricardo M. de Oliveira Soares, MD, answers a question during a Zoom video interview
Rachel Pope, MD, MPH, answers a question during a Zoom video interview
Related Content
© 2023 MJH Life Sciences

All rights reserved.